Study S001344

Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study

ClinicalTrials.gov record

Registration

Registration: NCT03087032
Acronym: LiraGooD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 164
Start: 2019-01-10
Primary completion: 2025-01-15
Lead sponsor: The First Affiliated Hospital of Xiamen University
Conditions: Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic)
Interventions: DRUG:Liraglutide; DRUG:insulin glargine
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

the proportion of patients with HbA1c < 7.0% without experiencing hypoglycemia and without weight gain,with a superiority margin of 3% [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.